Xenon Pharmaceuticals Inc (XENE)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

200 - 3650 GILMORE WAY BURNABY, BRITISH COLUMBIA, CANADA V5G 48W

Xenon is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. The Company is advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.

Data as of 2021-08-02 08:42:37 -0400
Market Cap707.504 Million Shares Outstanding40.967 Million Avg 30-day Volume138.333 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE28.78 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.76455 52-week High/Low21.94 / 9.32 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -43.1295
Data provided by IEX Cloud
View SEC Filings from XENE instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 1 100.0% 2 (0.12%) 1 (0.06%) 100.0%
Funds Holding: 92 81 13.58% 36 (2.11%) 32 (1.86%) 12.5%
13F shares: 32.964 Million 28.021 Million 17.64% 21.825 Million 18.293 Million 19.3%
% Ownership 92.0554 80.0427 15.01% 60.9479 52.256 16.63%
New Positions: 14 10 40.0% 5 2 150.0%
Increased Positions 33 25 32.0% 19 9 111.11%
Closed Positions 4 8 -50.0% 1 3 -66.67%
Reduced Positions 24 21 14.29% 9 12 -25.0%
Total Calls 155.279 Thousand 1 Thousand 15427.9% 150.272 Thousand
Total Puts 0
PUT/CALL Ratio 0.0 0.0 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding XENE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding XENE BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

AZAB MOHAMMAD

  • Director
10,000 2021-06-03 2

HAYDEN MICHAEL R

  • Director
10,000 2021-06-03 3

MORTIMER IAN PRESIDENT & CEO

  • Officer
  • Director
125,000 2021-06-03 2

GANNON STEVEN

  • Director
10,000 2021-06-03 1

SVORONOS DAWN

  • Director
10,000 2021-06-03 1

MACHADO PATRICK

  • Director
10,000 2021-06-03 3

AULIN SHERRY CHIEF FINANCIAL OFFICER

  • Officer
100,000 2021-06-03 2

GAROFALO ELIZABETH A.

  • Director
0 2021-06-03 2

ROBIN SHERRINGTON EVP, STRATEGY & INNOVATION

  • Officer
32,232 2021-05-28 2

HOLLER FRANK A

  • Director
144,837 2021-05-27 1

PIMSTONE SIMON N. CEO

  • Officer
  • Director
227,743 2021-05-24 3

TARNOW MICHAEL M

  • Director
77,942 2021-05-18 2

PATOU GARY

  • Director
46,173 2021-03-17 2

EMPFIELD JAMES R. EVP, DRUG DISCOVERY

  • Officer
65,000 2021-03-12 1

VON SEGGERN CHRISTOPHER CHIEF COMMERCIAL OFFICER

  • Officer
60,000 2021-03-12 3

DESJARDINS CLARISSA

  • Director
0 2020-06-01 0

AYCARDI-FONSECA ERNESTO CMO

  • Officer
0 2020-03-12 0

SCHELLER RICHARD H

  • Director
0 2019-09-16 0

COHEN CHARLES J. VP, BIOLOGY

  • Officer
6,550 2018-12-11 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
No longer subject to file 2018-03-27 0

GOLDBERG Y. PAUL SVP, CLINICAL DEVELOPMENT

  • Officer
0 2017-10-23 0

WINQUIST RAYMOND HEAD, TRANSLATIONAL RESEARCH

  • Officer
1,000 2017-08-18 0

EVANS JOHNSTON L

  • Director
0 2015-05-04 0

STEIN EVAN A.

  • Director
No longer subject to file 2015-04-30 0

CORRAINI KAREN G. GEN. COUNSEL & CORP. SECRETARY

  • Officer
0 2015-03-17 0

MX ASSOCIATES, LLP

  • 10% Owner
No longer subject to file 2014-12-31 0

BRIDGER GARY EVP, RESEARCH & DEVELOPMENT

  • Officer
0 2014-11-21 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
XENON PHARMACEUTICALS INC XENE 2021-08-03 14:45:04 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-03 14:15:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-03 13:45:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-03 13:15:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-03 12:45:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 22:15:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 21:45:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 21:15:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 20:45:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 20:15:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 19:45:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 19:15:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 18:45:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 18:15:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 17:45:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 17:15:03 UTC -0.338 0.398 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 16:45:03 UTC -0.3397 0.4197 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 16:15:03 UTC -0.3397 0.4197 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 15:45:03 UTC -0.3397 0.4197 150000
XENON PHARMACEUTICALS INC XENE 2021-08-02 15:15:03 UTC -0.3397 0.4197 150000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund XENE -5.0 shares, $-56.7 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund XENE -4.0 shares, $-45.36 2020-03-31 N-PORT

Elevate your investments